COMMUNIQUÉS West-GlobeNewswire

Groupe Santé Devonian annonce le lancement commercial du traitement anti-âge Purgenesis(MC) à la conférence annuelle de l’Association canadienne de dermatologie

26/06/2018 - 14:45

Premier lancement de la gamme de produits de soin de la peau Purgenesis MC La première et l’unique gamme de produits distribuée par les dermatologues portant le seau du Programme de santé de la peau MC de l’Association [...]

UPDATE -- ZEMDRI™ (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)

26/06/2018 - 14:33

― ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae ― ― ZEMDRI is the only once-daily aminoglycoside therapy approved for use in cUTI ― ― ZEMDRI has [...]

Avinger Announces Successful Treatment of First Patients with Next-Generation Pantheris in Several Centers throughout the US

26/06/2018 - 14:30

REDWOOD CITY, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that several physicians have [...]

Progenics Pharmaceuticals Completes Enrollment of Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL™ in Prostate Cancer

26/06/2018 - 14:30

Top-line Data Expected in 4Q2018 NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and [...]

MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy

26/06/2018 - 14:30

Topline Data Anticipated in Second Half 2020 SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine [...]

David King Joins Fluidigm as Vice President, Research and Development, Genomics

26/06/2018 - 14:30

SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of David King as Vice President, Research and Development, Genomics. As a member of the [...]

Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial

26/06/2018 - 14:00

Iomab-B remains the only targeted conditioning treatment in clinical trials with the potential to increase access to and improve outcomes of bone marrow transplant NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- Actinium [...]

Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China

26/06/2018 - 14:00

- Agios to Receive $12 Million Upfront Payment and is Eligible to Receive Development, Regulatory, and Sales-Based Milestones and Tiered Royalties - - Collaboration Provides Opportunity for Patients with IDH1m Cancers [...]

PhaseBio Names Michael B. York as Vice President of Corporate Development and Commercial Strategy

26/06/2018 - 14:00

MALVERN, Pa., June 26, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for orphan diseases with an initial focus on [...]

Transplantation Pioneer Dr. Leonard Bailey Co-Founds ADiTx Therapeutics, Inc. to Develop Immune Modulation Treatment for Extending the Life of Transplanted Organs

26/06/2018 - 14:00

Novel ADi technology designed to therapeutically induce immune tolerance to transplanted tissues LOMA LINDA, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- Founders and management comprised of scientific experts and [...]

aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate

26/06/2018 - 14:00

ATYR1923 Well-Tolerated at all Doses Tested, with No Significant Adverse Events Pharmacokinetic Profile Supports Potential Once-Monthly Dosing SAN DIEGO, June 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE [...]

Nu-Med Plus, Inc. Selects s2s Public Relations firm as its Strategic Partner

26/06/2018 - 14:00

The firm specializes in driving investor interest SALT LAKE CITY, June 26, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc . (OTCQB:NUMD), a medical device company which investigates and develops nitric oxide applications of [...]

7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program

26/06/2018 - 14:00

HOUSTON, June 26, 2018 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a privately-held immunotherapy company focused on development of novel tumor-targeting cell adhesion agents, announced today the formation of its Scientific [...]

ZEMDRITM (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)

26/06/2018 - 14:00

― ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae ― ― ZEMDRI is the only once-daily aminoglycoside therapy approved for use in cUTI ― ― ZEMDRI has [...]

Precipio and Nucleai Partner to Develop Artificial Intelligence-Powered Hemepath Solution

26/06/2018 - 14:00

System will support Hematopathologists in accurately identifying abnormalities to ensure diagnostic accuracy NEW HAVEN, Conn., June 26, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO [...]

Arch Therapeutics Provides Skin Sensitization Study Status Update

26/06/2018 - 13:50

Approximately two-thirds of applications in the repeat dosing induction phase are completed; Study remains on track FRAMINGHAM, Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or [...]

SELLAS Life Sciences Announces Proposed Public Offering of Common Stock

26/06/2018 - 13:46

NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or “the Company”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range [...]

Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual Meeting

26/06/2018 - 10:00

Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual Meeting Leading cancer supportive care experts in oncology explore how to provide the best care for patients by discussing the importance [...]

Solon Eiendom ASA : Primary insider notification

26/06/2018 - 08:31

(Oslo, Norway, June 25, 2018) UFI AS has today bought 38.664 shares in Solon Eiendom ASA at a price of NOK 29.9097 per share. Solon Eiendom ASA Board Member Øystein A. Landvik owns 33,34 % of the shares in UFI AS. [...]